Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Saved in:
| Title: | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis. |
|---|---|
| Authors: | Dunn K; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA., Bushen J; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA., Luo D; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cai J; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA., Simonson RB; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA., Anderson D; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA. |
| Source: | HIV medicine [HIV Med] 2023 Mar; Vol. 24 (3), pp. 279-289. Date of Electronic Publication: 2022 Aug 15. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 100897392 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1293 (Electronic) Linking ISSN: 14642662 NLM ISO Abbreviation: HIV Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
